James D. Reimann

4.0k total citations · 3 hit papers
16 papers, 3.0k citations indexed

About

James D. Reimann is a scholar working on Physiology, Immunology and Allergy and Surgery. According to data from OpenAlex, James D. Reimann has authored 16 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Physiology, 5 papers in Immunology and Allergy and 4 papers in Surgery. Recurrent topics in James D. Reimann's work include Allergic Rhinitis and Sensitization (5 papers), Asthma and respiratory diseases (5 papers) and Food Allergy and Anaphylaxis Research (3 papers). James D. Reimann is often cited by papers focused on Allergic Rhinitis and Sensitization (5 papers), Asthma and respiratory diseases (5 papers) and Food Allergy and Anaphylaxis Research (3 papers). James D. Reimann collaborates with scholars based in United States, Germany and United Kingdom. James D. Reimann's co-authors include John Q. Su, Robert B. Fick, Kathy D. Miller, Melody Cobleigh, Hope S. Rugo, Virginia K. Langmuir, Frankie A. Holmes, Linnea Chap, Amy P. Sing and Beth Overmoyer and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Journal of the American College of Cardiology.

In The Last Decade

James D. Reimann

16 papers receiving 2.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer

2005 1.0k citations Kathy D. Miller, Linnea Chap et al. Journal of Clinical Oncology profile →
The Effect of an Anti-IgE Monoclonal Antibody on the Early- and Late-Phase Responses to Allergen Inhalation in Asthmatic Subjects

1997 521 citations John V. Fahy, Hofer Wong et al. American Journal of Respiratory and Critical Care Medicine profile →
Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody

1999 520 citations Henry Milgrom, Robert B. Fick et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James D. Reimann United States	12	1.1k	967	864	813	607	16	3.0k
W. J. Mooi Netherlands	26	201 0.2×	1.2k 1.2×	76 0.1×	840 1.0×	1.1k 1.7×	60	2.7k
Valentin Goede Germany	27	131 0.1×	777 0.8×	92 0.1×	445 0.5×	1.0k 1.7×	76	3.2k
Karin Bowen United States	15	1.0k 0.9×	1.3k 1.3×	338 0.4×	942 1.2×	809 1.3×	30	2.8k
Masao Hosokawa Japan	36	163 0.1×	852 0.9×	121 0.1×	1.7k 2.1×	1.2k 1.9×	112	3.8k
Hiroyoshi Ayabe Japan	28	114 0.1×	802 0.8×	88 0.1×	1.1k 1.3×	680 1.1×	205	2.6k
G Spencer-Green United States	19	93 0.1×	375 0.4×	126 0.1×	191 0.2×	510 0.8×	40	4.1k
Raymond L. Comenzo United States	44	601 0.5×	2.4k 2.5×	51 0.1×	234 0.3×	6.7k 11.1×	230	8.3k
Ali Amirkhosravi United States	27	37 0.0×	720 0.7×	225 0.3×	253 0.3×	685 1.1×	62	2.5k
Louis R. Bégin Canada	37	61 0.1×	1.6k 1.7×	224 0.3×	1.7k 2.0×	1.3k 2.2×	104	4.7k
Sebastian Aulmann Germany	31	238 0.2×	910 0.9×	29 0.0×	795 1.0×	1.0k 1.7×	74	2.4k

Countries citing papers authored by James D. Reimann

Since Specialization

Citations

This map shows the geographic impact of James D. Reimann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James D. Reimann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James D. Reimann more than expected).

Fields of papers citing papers by James D. Reimann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James D. Reimann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James D. Reimann. The network helps show where James D. Reimann may publish in the future.

Co-authorship network of co-authors of James D. Reimann

This figure shows the co-authorship network connecting the top 25 collaborators of James D. Reimann. A scholar is included among the top collaborators of James D. Reimann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James D. Reimann. James D. Reimann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Jubb, Adrian M., Kathy D. Miller, Hope S. Rugo, et al.. (2011). Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer. Clinical Cancer Research. 17(2). 372–381. 79 indexed citations

Corren, Jonathan, Gail Shapiro, James D. Reimann, et al.. (2008). Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. Journal of Allergy and Clinical Immunology. 121(2). 506–511. 50 indexed citations

Yepes-Rios, Monica, et al.. (2006). Colorectal Cancer Screening Among Mexican Americans at a Community Clinic. American Journal of Preventive Medicine. 30(3). 204–210. 37 indexed citations

Reddy, Josina C., James D. Reimann, Steven M. Anderson, & Pamela Klein. (2006). Concordance Between Central and Local Laboratory HER2 Testing from a Community-Based Clinical Study. Clinical Breast Cancer. 7(2). 153–157. 84 indexed citations

Rosenfeld, Philip J., Steven D. Schwartz, Mark S. Blumenkranz, et al.. (2005). Maximum Tolerated Dose of a Humanized Anti–Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular Degeneration. Ophthalmology. 112(6). 1048–1053.e4. 185 indexed citations

Miller, Kathy D., Linnea Chap, Frankie A. Holmes, et al.. (2005). Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer. Journal of Clinical Oncology. 23(4). 792–799. 1002 indexed citations breakdown →

Corren, Jonathan, David Díaz-Sánchez, Andrew Saxon, et al.. (2004). Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis. Annals of Allergy Asthma & Immunology. 93(3). 243–248. 24 indexed citations

Cook, David M., Beverly M. K. Biller, M. L. Vance, et al.. (2002). The Pharmacokinetic and Pharmacodynamic Characteristics of a Long-Acting Growth Hormone (GH) Preparation (Nutropin Depot) in GH-Deficient Adults. The Journal of Clinical Endocrinology & Metabolism. 87(10). 4508–4514. 75 indexed citations

Reimann, James D., Nishit B. Modi, & William Novotny. (2000). Pharmacokinetics and Pharmacodynamics of Sibrafiban, an Orally Administered GP IIb/IIIa Antagonist, following Coadministration of Aspirin and Heparin. The Journal of Clinical Pharmacology. 40(5). 488–495. 4 indexed citations

10.

Ault, Kenneth A., et al.. (1999). Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Journal of the American College of Cardiology. 33(3). 634–639. 204 indexed citations

11.

Modi, Nishit B., et al.. (1999). Pharmacokinetics and Pharmacodynamics of Sibrafiban, an Orally Administered IIb/IIIa Antagonist, in Patients with Acute Coronary Syndrome. The Journal of Clinical Pharmacology. 39(7). 675–684. 8 indexed citations

12.

Widjaja, A., et al.. (1999). Malabsorption with progressive weight loss and multiple intestinal ulcers in a patient with T-cell lymphoma.. PubMed. 37(7). 611–4. 2 indexed citations

13.

Milgrom, Henry, Robert B. Fick, John Q. Su, et al.. (1999). Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody. New England Journal of Medicine. 341(26). 1966–1973. 520 indexed citations breakdown →

14.

Fahy, John V., Hofer Wong, John Q. Su, et al.. (1997). The Effect of an Anti-IgE Monoclonal Antibody on the Early- and Late-Phase Responses to Allergen Inhalation in Asthmatic Subjects. American Journal of Respiratory and Critical Care Medicine. 155(6). 1828–1834. 521 indexed citations breakdown →

15.

Casale, Thomas B., Jonathan A. Bernstein, William W. Busse, et al.. (1997). Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis☆☆☆★★★. Journal of Allergy and Clinical Immunology. 100(1). 110–121. 244 indexed citations

16.

Fahy, J.V., Hofer Wong, James Liu, et al.. (1996). 702 The effect of treatment with a monoclonal antibody directed against IgE on allergic airway responses in asthmatic subjects. Journal of Allergy and Clinical Immunology. 97(1). 358–358. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact